Skip to content

Medicine Matters

Sharing successes, challenges and daily happenings in the Department of Medicine

Infectious Diseases

Glutamine metabolism inhibition has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis

ARTICLE: Glutamine metabolism inhibition has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis AUTHORS: Sadiya Parveen, Jessica Shen, Shichun Lun, Liang Zhao, Jesse Alt, Benjamin Koleske, Robert D Leone, Rana Rais, Jonathan D… Read More »Glutamine metabolism inhibition has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis

Biphasic decay of intact SHIV genomes following initiation of antiretroviral therapy complicates analysis of interventions targeting the reservoir

ARTICLE: Biphasic decay of intact SHIV genomes following initiation of antiretroviral therapy complicates analysis of interventions targeting the reservoir AUTHORS: Mithra R Kumar, Emily J Fray, Alexandra… Read More »Biphasic decay of intact SHIV genomes following initiation of antiretroviral therapy complicates analysis of interventions targeting the reservoir

Evidence for tuberculosis in individuals with Xpert Ultra “trace” sputum during screening of high-burden communities

ARTICLE: Evidence for tuberculosis in individuals with Xpert Ultra "trace" sputum during screening of high-burden communities AUTHORS: Joowhan Sung, Mariam Nantale, Annet Nalutaaya, Patrick Biché, James Mukiibi, Caleb E Kamoga, Joab… Read More »Evidence for tuberculosis in individuals with Xpert Ultra “trace” sputum during screening of high-burden communities

The impact of preventive treatment for multidrug- and rifampin-resistant tuberculosis exceeds trial-based estimates

ARTICLE: The impact of preventive treatment for multidrug- and rifampin-resistant tuberculosis exceeds trial-based estimates AUTHORS: Parastu Kasaie, Jeff Pennington, Amita Gupta, David W Dowdy, Emily A Kendall JOURNAL:… Read More »The impact of preventive treatment for multidrug- and rifampin-resistant tuberculosis exceeds trial-based estimates